Yu-Hua Fu

ORCID: 0009-0000-9978-0323
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Health Systems, Economic Evaluations, Quality of Life
  • Geriatric Care and Nursing Homes
  • Adenosine and Purinergic Signaling
  • Palliative Care and End-of-Life Issues
  • Lymphoma Diagnosis and Treatment
  • Pharmaceutical Practices and Patient Outcomes
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Lipoproteins and Cardiovascular Health
  • Dementia and Cognitive Impairment Research
  • Neurological Complications and Syndromes
  • Cardiac Imaging and Diagnostics
  • CAR-T cell therapy research
  • Cardiac Arrhythmias and Treatments
  • Atrial Fibrillation Management and Outcomes
  • Blood Pressure and Hypertension Studies

National Taiwan University
2022-2025

University of Maryland, Baltimore
2024

To identify cardiovascular (CV) risk factors in Asian elderly aged 75 years and older subsequently develop validate a sex-specific five-year CV assessment tool for this population. This study included 12,174 patients ≥ without prior history of disease at single hospital Taiwan. Electronic health records were linked to the National Health Insurance Research Database Death Registry ensure comprehensive information. Eligible randomly divided into derivation (80%) validation (20%) cohorts. A was...

10.1186/s12877-024-05660-4 article EN cc-by-nc-nd BMC Geriatrics 2025-01-08

<sec> <title>BACKGROUND</title> Pilot data suggest that off-label, unmonitored antiepileptic drug prescribing for behavioral and psychological symptoms of dementia is increasing, replacing other psychotropic medications targeted by purposeful reduction efforts. This trend accelerated during the COVID-19 pandemic. Although adverse outcomes related to this remain unknown, preliminary results hint harms may be increasing concentrated in vulnerable populations. </sec> <title>OBJECTIVE</title>...

10.2196/preprints.64446 preprint EN 2024-07-17

Background Pilot data suggest that off-label, unmonitored antiepileptic drug prescribing for behavioral and psychological symptoms of dementia is increasing, replacing other psychotropic medications targeted by purposeful reduction efforts. This trend accelerated during the COVID-19 pandemic. Although adverse outcomes related to this remain unknown, preliminary results hint harms may be increasing concentrated in vulnerable populations. Objective Using a mixed methods approach including both...

10.2196/64446 article EN cc-by JMIR Research Protocols 2024-09-19
Coming Soon ...